FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Similar documents
Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

STEP THERAPY CRITERIA

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

What s New in Diabetes Treatment. Disclosures

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

Diabetes Medications: Oral Anti-Hyperglycemic Medications

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

How can we improve outcomes in Type 2 diabetes?

SGLT2 Inhibitors

Drug Class Review Newer Diabetes Medications and Combinations

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Pharmacologic Agents for Treatment of Type 2 Diabetes

How they work and when to take them. Diabetes Medications

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

What s New in Diabetes Medications. Jena Torpin, PharmD

DM Fundamentals Class 4 Meds for Type 2

DM Fundamentals Class 4 Meds for Type 2

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Copyright 2003 How long does it take metformin to lower blood sugar. All rights reserved.

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Non-Insulin Diabetes Medications Summary

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

How to Fight Diabetes and Win. Diabetes. Medications

Diabetes Management: A diagnostic perspective

Very Practical Tips for Managing Type 2 Diabetes

Oral and Injectable Non-insulin Antihyperglycemic Agents

The Death of Sulfonylureas? A Review of New Diabetes Medications

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Date of Review: September 2016 Date of Last Review: September 2015

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Current and future market dynamics overview

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

Exploring Non-Insulin Therapies in Type 1 Diabetes

What s New on the Horizon: Diabetes Medication Update

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Exploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Diabetes Mellitus II CPG

Dept of Diabetes Main Desk

SGLT2 Inhibitors

Drugs used in Diabetes. Dr Andrew Smith

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

Navigating the New Options for the Management of Type 2 Diabetes

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes

Drug Class Review Monograph GPI Class 27 Anti-diabetics

I. General Considerations

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

Rebecca Newberry APRN MS CDE

Table 1. Antihyperglycemic agents for use in type 2 diabetes

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

Treatment Options for Diabetes: An Update

SGLT2 Inhibitors

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

Endo 2 SLO Practice (online) Page 1 of 7

Diabetes 2016: Strategies for achieving optimal diabetes control

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

TYP 2 DIABETES. Marc Donath

PATIENT INFORMATION LEAFLET MEDICINE TO TREAT: DIABETES

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

ORAL AND INJECTABLE (NON-INSULIN) PHARMACOLOGICAL AGENTS FOR TYPE 2 DIABETES

GLYXAMBI (empagliflozin-linagliptin) oral tablet

Glucose Control drug treatments

Advanced Practice Education Associates. Endocrine

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Medications for Type 2 Diabetes CDE Exam Preparation

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Collaborative Practice Agreement

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

SGLT2 Inhibitors

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Clinical Cases in Diabetes Management. Joseph Cook D.O.

PRIOR AUTHORIZATION BYPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Diabetes Drugs by Class

Diabetes Treatment Guidelines

GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018

3. Cardiovascular Disease?

PRIOR AUTHORIZATION BYPASS Bydureon (long acting exenatide)

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Transcription:

Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your urine. When blood sugar levels reach a certain point and the body has more than it needs, the kidneys help get rid of some of the sugar naturally, through the urine. In people with type 2 diabetes, this may not happen until blood sugar levels reach a higher point. As blood sugar levels climb, the kidneys and the body may hold on to more sugar instead of getting rid of it. FARXIGA works with your kidneys to remove some sugar in the urine when your body has more than it needs. FARXIGA (dapagliflozin) Pharmaceuticals LP 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. sodium glucose co-transporter-2 (SGLT2) inhibitor JARDIANCE works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with T2D who have elevated blood glucose levels. SYNJARDY works by helping to control blood glucose in people with T2D. SYNJARDY removes excess glucose through the urine by blocking glucose re-absorption in the kidney while lowering glucose production by the liver and its absorption in the intestine. Jardiance (empagliflozin) tablets Synjardy (empagliflozin and metformin hydrochloride) tablets Ingelheim Marketed Ingelheim and Eli Lilly and Ingelheim Marketed Ingelheim and Eli Lilly and The recommended dose of JARDIANCE is 10 mg once daily, taken in the morning, with or without food. The recommended dose of SYNJARDY is 5 mg SENSITIZERS Biguanides: These drugs work by decreasing the liver s glucose production. GLUCOPHAGE* (metformin) GLUCOPHAGE XR* Extended-release tablets (metformin) Bristol-Myers Squibb Bristol-Myers Squibb Generally, significant effects are not seen with doses below 1,500 mg a day, but starting with lower doses and gradually increasing is recommended to minimize gastrointestinal reactions. The suggested starting dose is one 500 mg tablet taken with both the morning and evening meals, or one 850 mg tablet taken once a day with the morning meal. The usual starting dose is 500 mg or 750 mg, taken once daily with the evening meal. * Lactic acidosis a rare but very serious (often fatal) complication has been associated with the use of Glucophage (metformin). However, the reported incidence of lactic acidosis in people taking this medication is very low. Lactic acidosis happens more often in people with kidney problems. Signs of lactic acidosis are feeling very weak, tired, or uncomfortable; experiencing unusual muscle pain, trouble breathing, or unusual stomach discomfort; feeling cold, dizzy, or lightheaded; or suddenly developing a slow or irregular heartbeat. Contact your physician if your medical condition suddenly changes. 20 www.diabeteshealth.com / DIABETES HEALTH

Max Daily Dose Side Effects and Special Considerations For more information, please see Full Prescribing Information, including Patient Information at https://www.farxiga.com/ 10 mg once daily, taken in the morning, with or without food For more information, please see Full Prescribing Information, including Patient Information at https://www.jardiance.com/ Dose may be increased to 25 mg once daily For more information, please see Full Prescribing Information, including Patient Information at https://www.synjardy.com/ Dose may be increased to 12.5 mg empagliflozin/ 1000 mg metformin twice daily empagliflozin/500 mg metformin twice daily with meals For more information, please see Full Prescribing Information, including Patient Information at www.riomet.com GLUCOPHAGE* (metformin) GLUCOPHAGE XR* Extended release tablets (metformin) www.diabeteshealth.com / DIABETES HEALTH 21

Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose STARCH BLOCKERS Alpha-Glucosidase Inhibitors: These drugs work in the intestines to slow the digestion of some carbohydrates so that after-meal blood glucose peaks are not so high. These drugs enhance a natural body system called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. The mechanism of action of DPP-4 inhibitors is glucose-dependent, responding to the presence of elevated glucose and resulting in the release of insulin and decrease of glucagons only when needed, thereby lowering the potential for hypoglycemia. PRECOSE (acarbose) GLYSET (miglitol) JANUVIA (sitagliptin) Bayer Pharmacia Upjohn Merck & Co., Inc. 25 mg (half a 50 mg tablet), taken orally three times a day at the start of each main meal. 25 mg to 50 mg taken with meals. 100 mg once daily, with or without food, for all approved indications. Max Daily Dose 150-300 mg per day (100 mg with each meal) 300 mg per day (100 mg with each meal) 100 mg once daily ONGLYZA works by enhancing the body s natural ability to control blood sugar by helping increase the level of insulin after meals. This may result in lower after-meal blood sugar spikes. ONGLYZA also reduces the amount of sugar released by the liver overnight and between meals. This may result in lower blood sugar in the morning and between meals. Pharmaceutical LP. 5 mg once daily taken regardless of meals. 5 mg once daily taken regardless of meals DPP-4 INHIBITORS TRADJENTA works by increasing hormones that stimulate your pancreas to produce more insulin and stimulate the liver to produce less glucose. ONGLYZA (saxagliptin) Tradjenta (linagliptin) Ingelheim Boehringer Ingelheim and The recommended dose of TRADJENTA is one 5 mg tablet once a day, with or without food N/A JENTADUETO XR works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. JENTADUETO XR (linagliptin and metformin hydrochloride extended-release) tablets Ingelheim Boehringer Ingelheim and The recommended dose of JENTADUETO XR is 2.5 mg or 5 mg linagliptin with 1000 mg metformin. Max daily dosage should not exceed 5 mg linagliptin and 2000 mg metformin. SGLT2/DPP-4 GLYXAMBI works by removing glucose through the urine by blocking blood glucose re-absorption in the kidney, while also increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose. Glyxambi (empagliflozin/ linagliptin) tablet Ingelheim Boehringer Ingelheim and The recommended dose of GLYXAMBI is 10/5 mg once daily, taken in the morning, with or without food Dose may be increased to 25/5 mg, once daily 22 www.diabeteshealth.com / DIABETES HEALTH

Side Effects and Special Considerations Abdominal pain, flatulence, and diarrhea tend to return to pretreatment levels as therapy continues. Take with the first bite of food for maximum effectiveness. Not approved for use during pregnancy or lactation. When these medications are used in combination with insulin, meglitinides, or sulfonylureas, hypoglycemia may occur and must be treated with pure glucose (tablets or gel) or milk because Precose and Glyset delay the absorption of other carbohydrates. For more information, please see Full Prescribing Information, including Patient Information at https://www.januvia.com/ For more information, please see Full Prescribing Information, including Patient Information at https://www.onglyza.com/ For more information, please see Full Prescribing Information, including Patient Information at https://www.tradjenta.com/ For more information, please see Full Prescribing Information, including Patient Information at https://www.jentadueto.com/ For more information, please see Full Prescribing Information, including Patient Information at https://www.glyxambi.com/ www.diabeteshealth.com / DIABETES HEALTH 23

Type 2 Medications Drug Class How It Works Adlyxin is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise. Brand and Generic Names Adlyxin (lixisenatide) injection Manufacturers Sanofi is the manufacturer. Adlyxi is inlicensed from Zealand Pharma Usual Starting Dose 10 micrograms (14 days) GLP-1 Receptor Agonist AMYLIN MIMETIC BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise. BYETTA is not insulin and should not be taken instead of insulin. BYETTA can be used with Lantus (insulin glargine), which is a long-acting insulin, but should not be taken with short- and/or rapid-acting insulin. BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis (a condition caused by very high blood sugar). BYETTA is not recommended for use in children. BYETTA has not been studied in people who have pancreatitis. BYETTA should not be used in people who have severe kidney problems. After eating a meal, the blood sugar level goes up. When the body senses this rise in blood sugar, BYETTA (exenatide) injection helps enhance the body's ability to release its own insulin. When the body senses your blood sugar has come down, the release of insulin slows. BYETTA is not insulin and should not be taken instead of insulin. BYETTA helps the body release its own insulin. When used with diet and exercise, BYETTA works to help improve blood sugar levels in the following ways: Helps the pancreas release insulin when needed Stops the release of a hormone that triggers the liver to make sugar when not needed Improves insulin response after meals Slows down how quickly stomach empties, sending sugar into blood more slowly Helps reduce amount of food intake (BYETTA is not a weight-loss product. Individual results may vary.) Victoza is an injectable type 2 diabetes medication. However, it is not insulin and does not contain insulin. Victoza has been studied in combination with basal insulin. It has not been studied in combination with prandial insulin. It can be taken with other diabetes medications, including metformin, sulfonylureas, and basal insulin and TZDs under a doctor s prescription. Victoza is 97 percent similar to a hormone made in the body called glucagon-like peptide-1, or GLP-1. When a person eats, GLP-1 helps the beta cells in the pancreas release the right amount of insulin to move sugar from the blood into the cells. Victoza has the same effect and also helps slow down the time it takes for food to leave the stomach, which can help the body manage its blood sugar level. Victoza also prevents the liver from releasing too much sugar by lowering the amount of another hormone, glucagon. BYDUREON is a once-weekly, non-insulin injection medicine that may help improve blood sugar in adults with type 2 diabetes. BYDUREON should be used along with diet and exercise and any oral medication currently being taken. BYDUREON is not recommended as the first medication to treat diabetes. BYDUREON works in the body to: Help the pancreas release insulin when needed Prevent the release of sugar when it's not needed Slow down how quickly the stomach digests food, to send sugar into the blood more slowly Help reduce the amount of food intake (BYDUREON is not a weight-loss drug. Individual results may vary.) BYDUREON is not recommended as the first choice of medicine for treating diabetes. BYDUREON is not a substitute for insulin and is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYDUREON is a long-acting form of the medication in BYETTA (exenatide) injection so both drugs should not be used at the same time. It is not known if BYDUREON can be used in people with a history of pancreatitis or if BYDUREON is safe and effective for use in children. Trulicity is a once-weekly injectable prescription medicine to improve blood sugar in adults with type 2 diabetes. It should be used along with diet and exercise. SYMLIN is a synthetic analog of human amylin that can help lower blood sugar in adults with type 1 and type 2 diabetes treated with mealtime insulin. SYMLIN works in the body in three ways: SYMLIN suppresses the release of glucagon, a hormone that tells your liver to release sugar into the bloodstream. SYMLIN slows the rate food moves from the stomach into the small intestine. SYMLIN makes you feel full at meals which makes you eat less (SYMLIN is not a weight-loss product. Individual results may vary). BYETTA (exenatide) injection Victoza (liraglutide [rdna origin]injection) BYDUREON (exenatide extended-release) for injectable suspension) Trulicity (dulaglutide) Symlin Pen TM (pramlintide acetate) pen-injector Pharmaceuticals LP Novo Nordisk Victoza Pharmaceuticals LP by: Eli Lilly and Pharmaceuticals LP Initiate at 5 micrograms twice daily (at any time within the 60-minutes before the two main meals of the day, approximately 6 hours or more apart); based on clinical response after 1 month, dose may be increased to 10 micrograms twice daily, as above. For all patients, Victoza should be initated with a dose of 0.6 mg per day for one week. The 0.6 mg dose is a starting dose intended to reduce gastrointestinal symptoms during inital titration, and is not effective for glycemic control. After one week at 0.6 mg per day, the dose should be increased to 1.2 mg. If the 1.2 mg dose does not result in acceptable glycemic control, the dose can be increased to 1.8 mg. Administer 2 mg by subcutaneous injection once every seven days (weekly), at any time of day and with or without meals. Trulicity comes in two doses - one with a yellow label (0.75 mg), the other with a blue label (1.5 mg). Your healthcare provider will tell you which one is right for you. The amount of Symlin used depends on whether the patient has type 1 or type 2 diabetes. When starting SYMLIN, the dose of Insulin should be reduced to half. Never mix SYMLIN and insulin. For type 2: Start SYMLIN at 60 mcg injected subcutaneously, just before major meals (meal must have at least 250 calories or 30 grams of carbohydrate). For type 1: Start SYMLIN at 15 mcg injected subcutaneously, just before major meals (meal must have at least 250 calories or 30 grams of carbohydrate). 24 www.diabeteshealth.com / DIABETES HEALTH

Max Daily Dose Side Effects and Special Considerations For more information, please see Full Prescribing Information, including Patient Information at http://products.sanofi.us/adlyxin/adlyxin.pdf 20 micrograms For more information, please see Full Prescribing Information, including Patient Information at https://www.byetta.com/ 10 micrograms/ twice a day For more information, please see Full Prescribing Information, including Patient Information at https://www.victoza.com/ 1.8 mg For more information, please see Full Prescribing Information, including Patient Information at https://www.bydureon.com/home.html 2 mg once every seven days Recommended starting dose is 0.75 mg. Dose may be increased to 1.5 mg for additional glycemic control. For more information, please see Full Prescribing Information, including Patient Information at https://www.trulicity.com/ For more information, please see Full Prescribing Information, including Patient Information at https://www.symlin.com/ Type 2: 120 mcg; Type 1: 60 mcg with main meals www.diabeteshealth.com / DIABETES HEALTH 25